The team at Morgans has been busy looking at its financial models for a number of ASX dividend stocks.
Two that have fared well and been given buy ratings following their results releases are named below. Here's why Morgans remains bullish on these stocks:
Image source: Getty Images
IPH Ltd (ASX: IPH)
Morgans continues to recommend this intellectual property services company to clients.
In response to its half-year results, the broker has put a buy rating and $5.39 price target on the ASX dividend stock. It said:
IPH's 1H26 result was broadly in line with consensus, reporting like-for-like (LFL) revenue and EBITDA growth at the group level. Whilst Canada and Asia showed growth, ANZ remains impacted by lower US PCT filings. IPH's valuation is undemanding (<8x FY27F PE), however we note investor patience is required given the delivery of organic growth (and return of key US PCT's) looks to be the catalyst for a sustained re-rating. Maintain Buy recommendation.
As for income, Morgans is forecasting fully franked dividends of 38 cents per share in FY 2026 and then 39 cents per share in FY 2027. Based on its current share price of $3.67, this equates to very generous dividend yields of 10.3% and 10.6%, respectively.
Sonic Healthcare Ltd (ASX: SHL)
Another ASX dividend stock that is rated highly by the team at Morgans is Sonic Healthcare.
It responded to its better than expected half-year results by retaining its buy rating with a trimmed price target of $28.64. It said:
1HFY26 result was better than expected, with underlying NPAT c4% ahead and organic revenue growth of 5%, demonstrating resilience across most regions. Underlying EBITDA was broadly in line, margins expanded and cost discipline remained evident. Importantly, FY26 guidance was maintained, an operational review of the US business is underway, and sale-and-leaseback activity introduces capital management optionality.
While structural growth remains moderate, we view the result as evidence that the market's "broken core" narrative has been overstated. Execution now becomes the key driver, but at subdued trading levels, the risk/reward skews favourably. We adjust FY26-28 estimates (mainly FX related), with our target price decreasing to A$28.64. BUY.
With respect to income, the team at Morgans is expecting Sonic Healthcare to reward shareholders with dividends per share of $1.08 in FY 2026 and then $1.11 in FY 2027. Based on its current share price of $23.02, this would mean dividend yields of 4.7% and 4.8%, respectively.
